N/A
Completed N=402
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Source: ClinicalTrials.gov NCT01555762 ↗Enrolled (actual)
402
Serious AEs
25.6%
Results posted
Jan 2019
Primary outcomePrimary: Progression-Free Survival — 9.14 Months
Summary
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer. Data will be collected from eligible patients for24 months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-Free Survival |
9.14 | — |
| SECONDARY Overall Survival |
19.00 | — |
| SECONDARY Percentage of Participants With Bevacizumab Administration |
90.8; 7.3; 1.7; 12.3; 82.4 | — |
| SECONDARY Percentage of Participants With Adverse Events (AEs) |
60.8 | — |
| SECONDARY Percentage of Participants With Activities of Daily Living (ADL) |
89.2; 8.2; 2.5; 92.9; 4.2; 2.8 | — |
| SECONDARY Lawton Instrumental Activities of Daily Living Score (IADL) |
0.9; 1.0; 1.0; 0.8 | — |
| SECONDARY Percentage of Participants With Balducci Score |
36.8; 38.8; 21.1; 3.4; 37.3; 36.9 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients, >/= 75 years of age
- Metastatic colorectal cancer
- Initiating Avastin first-line therapy in combination with chemotherapy
Exclusion Criteria
- Previous Avastin therapy
- Patient participating in a clinical study evaluating a cytotoxic anti-cancer therapy and/or an investigational new drug
Data sourced from ClinicalTrials.gov (NCT01555762). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.